We are delighted to announce that Great Place to Work ™ have awarded the NCRI with the prestigious Best Workplaces™ for Health & Wellbeing 2025! This achievement reflects our commitment to fostering a supportive and healthy environment for all employees.
The European Cancer Information System (ECIS) has been updated with the latest cancer indicators computed from European population-based cancer registries’ data, including data from the National Cancer Registry Ireland.
A new report published by the NCRI shows good news for skin cancer patients with most people (close to 100%) surviving at least five years after being diagnosed with non-melanoma skin cancer.
World Cancer Day 2025 falls on 4 February. The NCRI believes that tackling the complexities of cancer requires a united effort. We’re shining a light on the international projects we contribute to in order to improve cancer registration across the globe.
The NCRI annual report on national cancer statistics examines variation in cancer incidence and survival across new health regions, and provides an update on the status of cancer in Ireland.
NCRI is proud to have been awarded the KeepWell Mark accreditation from IBEC for a second time – a reflection of our continued commitment to our employees’ wellbeing.
As many of us embark on our summer holidays in the next few weeks, the HSE National Cancer Control Programme (NCCP), the Irish Skin Foundation (ISF), and the National Cancer Registry of Ireland (NCRI) are reminding everyone of the importance of protecting skin from overexposure to the sun’s ultraviolet (UV) rays to reduce their risk of skin cancer.
The latest trends report on HPV-associated cancers estimates that there are 641 cases of new human papilloma virus (HPV)-associated cancers diagnosed and 196 cancer deaths per year in Ireland, most of which are potentially preventable by HPV vaccination.
The NCRI’s Strategic Plan sets out five key objectives and outlines the organisation’s continued commitment to work alongside Government and stakeholders to improve patient outcomes and enhance cancer control.
